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Discussion
Dr J. Brown (Indianapolis, Ind): Your experience with this op-
eration is clearly the largest and the best in the world. Mr Ross,
who is credited with this operation, did the autograft replacement
of the mitral valve in 8 patients before the 2 of you collaborated,
and then you have continued to modify his technique to make it
simpler and more reproducible. The pulmonary autograft has been
used in thousands of patients in the aortic valve position but in less
than 150 patients in the mitral position. The autograft is the only
potential durable bioprosthetic valve that is available for the mitral
position. As a congenital heart surgeon, I use this operation for a
select group of patients who cannot be treated with other alterna-
tives. We have had excellent results in our small series of 8
patients with the pulmonary autograft, except in 2 or 3 patients in
whom unacceptable mitral regurgitation developed because 1 of
the leaflets stretched.
Do you aggressively treat systemic hypertension in your pa-
tients postoperatively to prevent stretching of the pulmonary au-
tograft leaflets until they adapt to left ventricular systolic pressure?
What is your graft material of choice to support your autograft?
The woven Dacron graft that we have used in the United States has
recently been discontinued. So we are looking for a woven graft
that is stiff enough. How would you select the graft size? Do you
use preoperative echo? And if you do use preoperative echo, how
much larger a graft do you select than the echo diameter of the
pulmonary autograft? And fourth, have the 2 children who under-
went this technique and had the grafts split shown evidence of
growth of their autograft?
Dr Kabbani: Yours has been one of the few teams who have
picked up this procedure and have been supportive of our endeavor
all along.
We have had no problem with the pulmonary hypertensive
patients. For some reason after the operation, after any operation,
on a stenotic valve, the pulmonary pressure just decreases, and we
have not had any reason to deal with these patients in a special
way.
As far as the graft material is concerned, we have used Dacron.
As you say, when we started using the newer soft variety, we had
this problem, and we reverted to autoclaving the material with
albumin, hoping to get some resilience; however, in another 2
patients the problem recurred, probably because the albumin was
washed away with warm blood. So now what we are doing is very
secure, and that is using BioGlue between the pericardium sleeve
and the Dacron material. This makes the substance of the conduit
quite firm, and we have had no problem since.
In regard to the sizing of the graft, we take the eyeball sizing of
the pulmonary artery and we take a size that is just slightly larger
than that. We have had no problem with the sizing at all, and this
is one thing that we don’t have to worry about in this operation.
Of the 2 children, 1 had endocarditis and we had to explant the
autograft a few years after the operation, and 1 is okay; he is in
Beirut, but the family will not bring him in to have another echo
so that we can know that the valve grew with the child. So I don’t
have an answer to your last question.
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Dr P. Granados (Malaga, Spain): Congratulations on your
work, Dr Kabbani. What is the fate of the homograft in these
patients, because we didn’t see any data? Did you take any
pharmacologic measures to prevent homograft deterioration?
Dr Kabbani: You are talking about the pulmonary homografts,
the homografts in the pulmonary position? Yes, we have 4 patients
who are starting to show stenosis; only 1 is critical and needs an
operation, but we have not operated on any of them yet.
No, we don’t give any special treatments, so far we have not
done so, to prevent stenosis in the pulmonary homografts.
Dr M. del Rio (Riverside, Calif): Insofar as the autograft, I
have toyed around with a hybrid valve for which one uses 2 leaflets
of the pulmonary valve and retains 1 of the leaflets of the mitral
valve and insets that into the mitral position. Has that ever been
tried at your institution or tested in that way?
Dr Kabbani: No.
Dr del Rio: All right.
Dr J. Fragata (Lisbon, Portugal): I was always a bit reluctant
to perform the Ross operation in patients with rheumatic fever or
a history of rheumatic fever. Do you have any evidence or idea
whether the rheumatic process can continue in the autograft valve
in the mitral position and would you keep these patients on
antirheumatic prophylaxis?
Do you anticoagulate these patients? When we perform a
Fontan operation with a lateral tunnel, sometimes some clots go
around the prosthetic tube. I know this is covered with pericar-
dium, but don’t you get any clots around the tube in the floor of the
atrium, around the annulus of the mitral valve?
Dr Kabbani: The first question was regarding rheumatic ac-
tivity, and we expect that what we will have with the mitral
pulmonary autograft is similar to what was experienced by those
who did the classic Ross in the aortic position. Dr Al-Halees from
Saudi Arabia reported in his rheumatic series that approximately
10% of his patients had rheumatic activity in the autograft. There
was only 1 patient in whom we suspected that there was rheumatic
involvement in the pathology, but that was all in this series.
As for the second question, you are right, theoretically you
might have clots in that area between the autograft and the left
atrium, but we have had no problem from there. We anticoag-
ulate these patients for 3 months for a start, and then we stop if
the patient is in sinus rhythm. We anticoagulate them if they are
in atrial fibrillation for an international normalized ratio of 2 or
2.5.
Dr S. Yassin (Albuquerque, NM): How do you address the 4
patients in whom the autograft had to be sacrificed?
Dr Kabbani: I am sorry, I don’t understand the question.
Dr Yassin: You mentioned there were 4 patients in whom the
autograft could not be used. How did you address those patients?
Dr Kabbani: What did I do?
Dr Yassin: Yes.
Dr Kabbani: We just used a mechanical prosthesis instead. We
explanted them because there was a bent conduit causing obstruc-
tion. In 2 patients, we could do something about it; I don’t want to
take the time of the audience, but the 4 that we sacrificed were
replaced with a mechanical prosthesis.
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